Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,613.50
Bid: 1,613.00
Ask: 1,614.00
Change: -3.00 (-0.19%)
Spread: 1.00 (0.062%)
Open: 1,619.50
High: 1,622.50
Low: 1,609.50
Prev. Close: 1,616.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Unilever CEO set to leave after GSK debacle, arrival of activist investor

Mon, 26th Sep 2022 11:00

CEO Jope to retire at end 2023

*

Board begins search for successor

*

Peltz 'looking forward' to being part of choosing a new CEO

*

Shares hit highest in more than a year on news

Sept 26 (Reuters) - Unilever said CEO Alan Jope would retire at the end of 2023, announcing the move less than a year after a bungled attempt to buy GSK's consumer healthcare business, and two months after activist investor Nelson Peltz joined the board.

The British consumer products maker said its board would start a formal search for a successor to Jope, a Unilever veteran who took up his role at the start of 2019, considering both internal and external candidates.

Unilever's shares rose almost 4% in early trading, hitting their highest since August last year. They were up 1.2% at 1150 GMT.

The company's search begins at a time of soaring food and energy prices which are hitting household budgets and hurting consumer confidence. The company will be looking for a new CEO at the same time as rival Reckitt, the maker of Dettol products and Finish dish soap.

Unilever has had a rocky start to the year after mounting three bids for the consumer health arm of GlaxoSmithKline , - one for as much as 50 billion pounds ($53.14 billion).

The move was met with disapproval from shareholders, some of whom also criticised Unilever for prioritising sustainability over core growth.

"This may signal more welcome future change at Unilever," Tineke Frikee, fund manager at Unilever investor Waverton Asset Management, said.

"The unappealing plan to buy consumer healthcare from GlaxoSmithKline has tainted Mr Jope’s track record somewhat so a fresh start from a new CEO could convince investors Unilever’s momentum is trending upwards again."

The company in January also announced plans to cut about 1,500 management jobs and reshape its business to focus on five main product areas, days after it was revealed that Peltz, via his Trian Partners vehicle, had built a stake in Unilever.

Trian told Reuters in a statement that it was sorry to learn of Jope's decision to retire.

"As a board member, Trian’s CEO Nelson Peltz looks forward to continuing to work closely with Alan until his departure and to being part of the process of choosing a new leader for the company," it added.

A Unilever spokesperson said the company is "fully committed to the organisational changes" and that Jope is "completely committed to delivering against that strategy."

'A MIXED BAG'

Jope has worked at Unilever for more than 35 years, holding various senior leadership positions, including being head of the personal care division from 2014.

"I think Jope’s tenure as CEO was a bit of a mixed bag," Jack Martin, fund manager at Unilever shareholder Oberon Investments, said. "It has been a very impressive career nonetheless, joining as a trainee in the 80’s and ending up as CEO of one of the UK’s largest listed companies,"

Unilever's shares have underperformed European consumer staples and discretionary indices, as well as most rivals since Jope became CEO.

"Our immediate concern is that this leaves 15 months until his retirement with a CEO who might be seen to have lost credibility with employees and other stakeholders," RBC analyst James Edwardes Jones said.

"This at a time when Unilever will be implementing and bedding down a fundamental reorganisation, not to mention dealing with a challenging macro-economic environment."

A source familiar with the matter said Unilever's "unusual" decision to tell the market more than a year before Jope leaves stems from concerns that the news would have leaked before being officially announced.

"While his has undoubtedly been a great career, investors are likely to see this as a positive change, as the company has struggled in recent years to convince investors that it has the right brands and strategy to be a mid-single digit growth company," Bernstein analyst Bruno Monteyne said.

More News
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more
1 Sep 2023 07:49

LONDON BRIEFING: Stocks seen higher; UK house prices continue to fall

(Alliance News) - Stocks in London are set to open higher on Friday as markets looked ahead to a data-heavy day.

Read more
1 Sep 2023 07:12

Japan considering GSK's Nucala drug for sinusitis treatment

(Sharecast News) - Japanese regulators are reviewing a new drug application for GSK's Nucala treatment to be used for the treatment of form of adult sinusitis, the biopharma giant announced on Friday.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more
23 Aug 2023 08:17

GSK gets positive results from shingles trial of Shingrix in China

(Alliance News) - GSK PLC on Wednesday celebrated positive results from the first-ever efficacy trial of its preventative shingles treatment, Shingrix, in China.

Read more
23 Aug 2023 07:04

GSK reports positive results from shingles vaccine trials in China

(Sharecast News) - GSK reported significant positive findings from its first efficacy trial of the 'Shingrix' shingles vaccine in China on Wednesday.

Read more
22 Aug 2023 13:09

UK's Wood Group raises profit forecast on contract wins; shares rise

CFO David Kemp to retire

*

Read more
21 Aug 2023 22:37

US FDA approves Pfizer's maternal RSV vaccine to protect infants

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.

Read more
17 Aug 2023 19:53

Charity says HIV drug deal with GSK's ViiV on ice over price secrecy

(Alliance News) - The Doctors Without Borders, or MSF, charity said Thursday a deal aimed to bring long-term preventative HIV treatment to vulnerable populations was on hold after the drugmaker imposed pricing confidentiality.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.